This researcher has some ideas about what we need to do to address the problem.
Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
Ending the HIV Epidemic Is a Team Effort. The New York City and State Health Departments Discuss Their Combined Work
Johanne Morne, M.S., and Oni Blackstock, M.D., sat down with TheBody to discuss their successes and their work to close the disparities gap.
For people taking medications for HIV prevention, HIV treatment, STIs, or transgender health care, this couple -- in life and in business -- seeks to revolutionize the pharmacy experience at TIN Rx in San Francisco.
Primary care providers need more education when it comes to PrEP, not only for them, but also for patients, who often think they need to see a specialist just to take this preventative medicine.
Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results
Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.
On-demand pre-exposure prophylaxis may be best for people with episodic risk who cannot or would prefer not to take the pill every day.
A team led by Shannon Weber, M.S.W., has developed PleasePrEPMe, an online PrEP provider search and chat service.
PrEP (pre-exposure prophylaxis) is highly effective at preventing HIV, but uptake has been slow around the world. We asked providers and community leaders what they thought needed to happen for PrEP to reach everybody who needs it.